TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06044519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: different types of dressings
Description: different types of dressings were compared ti see the effectiveness for for STSG donor site wound
Study: NCT04747522

Intervention type: DRUG
Intervention: SARS-CoV-2 vaccine
Description: SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna

Intervention type: DRUG
Intervention: SARS-CoV-2 vaccine
Description: SARS-CoV-2 vaccines currently on market, i.e. Pfizer/BioNTech and Moderna
Study: NCT04011748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: AA subjects will be recruited and followed by the treatment with SCE therapy.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator therapy
Description: AA subjects will be recruited and followed by the treatment with SCE therapy.
Study: NCT06307392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First intubation attempt with endotracheal tube plus bougie
Description: Use of a straight, malleable, semirigid bougie on first-attempt intubation. The required bougie is at least 60cm length, a coudé tip is recommended but not required. Operator may choose whether to bend the bougie prior to intubation.~During laryngoscopy, the operator will insert the bougie into the trachea under direct or indirect visual control. If the bougie is successfully placed in the trachea, an assistant will load the endotracheal tube directly over the bougie while the operator will manually stabilize the bougie. Once the bougie has reached the mouth, the assistant will then stabilize the bougie, and the operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube. Then, the assistant will withdraw the bougie from the endotracheal tube.~The use of a stylet is not permitted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: First intubation attempt with endotracheal tube alone
Description: During laryngoscopy, the operator will insert the endotracheal tube alone into the trachea under direct or indirect visual control. The operator will advance the tube through the vocal cords to the adequate depth in the trachea, without removing the laryngoscope from the mouth. The operator will inflate the cuff and manually stabilize the tube.~The use of a stylet is not permitted.
Study: NCT03678545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (blinded)
Description: Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (blinded)
Description: Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab (open-label)
Description: After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dupilumab (open-label)
Description: After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
Study: NCT05099549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM24
Description: Tetravalent, bispecific EGFR- and CD16A-binding innate cell engager.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex-vivo expanded autologous natural killer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex-vivo expanded autologous natural killer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex-vivo expanded autologous natural killer cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex-vivo expanded autologous natural killer cells.
Study: NCT05514509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE
Description: Available as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE
Description: Available as intramuscular injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APRETUDE
Description: Available as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir tablet
Description: Available as marketed orally administered tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir tablet
Description: Available as marketed orally administered tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir tablet
Description: Available as marketed orally administered tablets.
Study: NCT05887037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mNGS
Description: mNGS is the direct extraction of nucleic acid from clinical samples. High-throughput sequencing technology and bioinformatics analysis were adopted to complete the detection of pathogens such as bacteria, fungi, viruses and parasites at one time

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: The traditional microbiological cultures
Description: Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The traditional microbiological cultures
Description: Traditional microbial culture is the gold standard for the diagnosis of central nervous system infection, but the traditional microbiological culture time is long and the detection rate is low.
Study: NCT06168383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 80mg
Description: once daily, oral administration of HSK31679 80mg from Day 1 to Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK31679 160mg
Description: once daily, oral administration of HSK31679 160mg from Day 1 to Week 52.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, oral administration of placebo from Day 1 to Week 52.
Study: NCT06322667

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT04718350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan at a dose of 6 mcg/kg
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone at a dose of 50 mcg/kg
Description: milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
Study: NCT06393777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: analgesic effect of honey
Study: NCT05161312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iACT-BC: Oncovox
Description: A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years
Study: NCT06528015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotics combined with enteric-coated budesonide capsule
Description: In the 9-month treatment period, the following treatments will be received: probiotics combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics (each bag added active probiotic Lactobacillus casei Zhang ≥100 billion CFU) +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: probiotics placebo combined with enteric-coated budesonide capsules
Description: In the 9-month treatment period, the following treatments will be received: probiotics placebo combined with enteric-coated budesonide capsules group: 1 bag/day of probiotics placebo +16 mg/day oral enteric-coated budesonide capsules.~After completing the treatment period, participants will enter a 2-week reduction period to reduce the risk of adrenal insufficiency. ① enteric-coated budesonide capsules reduction: 8 mg/day oral enteric-coated budesonide capsules.
Study: NCT06530238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Russian Currents
Description: Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Russian Currents
Description: Currents are delivered in rectangular bursts. The electrode placement will be at the Tibialis Posterior muscle. Treatment will be given for 10 minutes, 30 minutes during the 3 consecutive days / 4 weeks.
Study: NCT06393777

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: honey
Description: analgesic effect of honey
Study: NCT05443451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Ultrasound-Guided Transperineal Microwave needle ablation of BPH
Description: The procedure will consist of a focal, transperineal, targeted microwave ablation of prostate adenoma. Surgical planning using 3D transrectal ultrasound and real-time monitoring of the ablation would preserve key anatomical landmarks such as the bladder neck, prostatic urethra and verumontanum. The Organ-Based Tracking (OBT®) patented technology would provide a 3D prostate model to facilitate real-time navigation-guided ablation and accurate mapping of treatment zone. The procedure will be conducted under general anaesthesia, spinal anaesthesia, or monitored anaesthetic care / sedation. An average number of one to three microwave ablations per lobe is expected, depending on the size and shape of each prostate. The microwave ablation parameters will be chosen intraoperatively. A urinary catheter may be necessary immediately after the procedure. Patients are planned to be discharged on the same day or the day after when they are fit for discharge.
Study: NCT05995925

Intervention type: OTHER
Intervention: Clinical Observation
Description: Clinical Observation

Intervention type: OTHER
Intervention: Clinical Observation
Description: Clinical Observation
Study: NCT06159569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LACRIACT
Description: LACRIACT is is a preservative free ophthalmic sterile medical device solution. The solution is packaged in closable vials of inert material that does not affect the contents (clear low-density polyethylene), each vial contains 0.5 ml of solution.~Eligible patients will start the treatment. Patients will receive the box of eye drops, and will be instructed on how to self-administer 1 drop in each eye 4 times a day for 30 days starting from the day following the visit.
Study: NCT03372070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cNEP
Description: soft silicon collar applied to anterior neck with negative pressure
Study: NCT06034015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL-1202 and APL-1501 (Single ascending dose)
Description: Period 1 drug adminstration (APL-1202 IR tablet , single dose of 375mg will be administered orally on Day 1; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered as single dose on Day 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL-1202 and APL-1501 (Multiple Ascending dose)
Description: Period 1 drug adminstration (APL-1202 IR of 375mg will be administered thrice a day (TID) orally from Day 1 to Day 5; washout period of 72 hrs; Period 2 drug administration (APL-1501 ER capsules of 764mg, 1146 mg and 1528 mg will be administered twice daily (BID) from Day 9 to 13.
Study: NCT04600466

Intervention type: OTHER
Intervention: Molecular testing for all participants.
Description: Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.

Intervention type: OTHER
Intervention: Molecular testing for all participants.
Description: Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.
Study: NCT05165992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized Fentanyl
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Fentanyl
Description: Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
Study: NCT06517875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib will be administered orally.
Study: NCT05726175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: Disitamab Vedotin(RC48)：2.0mg/kg, iv, day1, q3weeks, 6 cycles in total;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab(AK105)：200mg, iv, day1, q3weeks, 6 cycles in total;
Study: NCT05619055

Intervention type: OTHER
Intervention: Routine treatment
Description: Antibiotics, intravenous fluids and symptomatic supportive treatment.
Study: NCT06517875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Luspatercept will be administered subcutaneously.
Study: NCT04677296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VS002A
Description: Amino acid based ORS/Medical food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO-ORS
Description: WHO Oral rehydration solution, which is glucose based
Study: NCT06444932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilization
Description: Patellofemoral and tibiofemoral joint mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: Patellofemoral and tibiofemoral joint mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Lower limb resistance exercise training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Description: Transcutaneous Electric Nerve Stimulation (TENS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electric Nerve Stimulation (TENS)
Description: Transcutaneous Electric Nerve Stimulation (TENS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heating Pad
Description: Heating pad for heat therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heating Pad
Description: Heating pad for heat therapy
Study: NCT05842421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography, in vivo reflectance confocal microscopy, 3D total body photography
Description: each lesion is in addition to examination with dermoscopy examined with optical coherence tomography, in vivo reflectance confocal microscopy, each patient is photographed with 3D total body photography
Study: NCT04701515

Intervention type: OTHER
Intervention: Chart review
Description: Chart review
Study: NCT05695170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PreventT2 (Individual intervention)
Description: PreventT2 will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the curriculum that will be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National Diabetes Prevention Program (DPP), which has full recognition from the CDC based on outcome data over the course of a number of years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PreventT2 Together (Couple-based intervention)
Description: PreventT2 Together will be delivered by a team of trained CDC Lifestyle Coaches to adults at high risk for diabetes and their partners. The curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevention type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
Study: NCT02493322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg
Description: 1 tablet a day
Study: NCT05876975

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic pectopexy
Description: Women with pelvic organ prolapse and suitable indications underwent laparoscopic pectopexy.
Study: NCT05561699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab Combined With CRT
Description: 1. Penpulimab: 200mg, intravenous infusion, once every two weeks. After completing two courses of CRT, continue to send Penpulimab 200mg every two weeks on the first and 14th days after the completion of CRT, two courses of treatment, a total of four courses.~2. Radiotherapy 40gy/20fx, once a day from Monday to Friday, completed in 4 weeks;~3. PC regimen: Paclitaxel 50mg/m2, intravenous drip, carboplatin AUC=2mg/ml/min, intravenous drip, once a week during radiotherapy, a total of 4 courses, the specific time is D1, 8, 15, 22 days after the beginning of radiotherapy.~4. Gastrointestinal reactions such as nausea and vomiting should be routinely prevented before chemotherapy. Dexamethasone 10mg should be used 30 \~ 60 minutes before paclitaxel, and intramuscular injection should be stopped immediately in case of drug or infusion reactions.
Study: NCT04375956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Experimental
Study: NCT02493322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20mg + Chlortalidone 25mg
Description: 1 tablet a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan 20mg + hydrochlorothiazide 12,5mg
Description: 1 tablet a day
Study: NCT06140277

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extraction with chitosan particles as a replacement for bone graft with collagen membrane
Description: to replace the bone at the extraction site we will put either chitosan or allograft particles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extraction with placing of allograft particles with collagen membrane
Description: to replace the bone at the extraction site we will put allograft particles

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: tooth extraction only
Description: hopeless tooth will be extracted without any intervention
Study: NCT05687708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Nutritive Sucking
Description: NNS is stimulated by giving stimulus into the baby's mouth with the help of a finger wearing gloves.
Study: NCT05137730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Description: Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Study: NCT06300346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Ondansetron
Study: NCT06322030

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOCUS-15 Lifestyle Management Program
Description: 15 week weight management program

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOCUS-15 Lifestyle Management Program
Description: 15 week weight management program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 15 weeks of progressive exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: 15 weeks of progressive exercise training
Study: NCT06300346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Ondansetron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Ondansetron